Hostname: page-component-84b7d79bbc-fnpn6 Total loading time: 0 Render date: 2024-07-29T22:10:04.407Z Has data issue: false hasContentIssue false
  • English
  • Français

HEALTH TECHNOLOGY ASSESSMENT IN SERBIA

Published online by Cambridge University Press:  30 June 2017

Dragana Atanasijevic  and
Vladimir Zah
Dragana Atanasijevic
Affiliation:
ISPORSerbiadratanas@yahoo.com
Vladimir Zah
Affiliation:
ISPORSerbia
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: This study provides an overview of the Republic of Serbia healthcare system and describes the process of developing and conducting health technology assessment (HTA).

Methods: The authors performed pragmatic, nonsystematic literature review based on available statistical data, legislation, and studies.

Results: Healthcare law creates conditions that allow implementation of the principle “value for money.” The institutions directly vested in the implementation of HTA are the National Health Insurance Fund (NHIF) and the Ministry of Health (MoH). There are some reflections of the efforts by NHIF and MoH toward achieving this goal.

Conclusions: Despite the highly set objectives, there is still a lot of work to be done to build an adequate model to support decision-making processes to bridge the discrepancies between broadly defined rights to health care and limited resources in the country.

Keywords

Republic of SerbiaHealth technology assessmentHTAHealthcare systemHealth insurance
Type
Theme Submissions
Information
International Journal of Technology Assessment in Health Care , Volume 33 , Issue 3: Theme: HTA in Central-Eastern-Southern Europe , 2017 , pp. 384 - 389
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1 The World Bank [Internet]. Serbia: The World Bank Group; c2016. http://www.worldbank.org/en/country/serbia (accessed December 8, 2016).Google Scholar
2 Statistical Office of the Republic of Serbia [Internet]. Serbia: Statistical Office of the Republic of Serbia; c2010. http://webrzs.stat.gov.rs/WebSite/Public/PageView.aspx?pKey=163 (accessed December 8, 2016).Google Scholar
3 Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2015 [Internet]. Serbia: Institute of Public Health of Serbia; 2016. http://www.batut.org.rs/download/publikacije/pub2015.pdf (accessed December 8, 2016).Google Scholar
4 Institute for Health Metrics and Evaluation. GBD PROFILE: SERBIA [Internet]. Seattle, WA: IHME; 2013. http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_serbia.pdf (accessed December 8, 2016).Google Scholar
5 The World Bank. Project appraisal document on a proposed credit in the amount of SDR 14.7 million (US$20 million equivalent) to Serbia and Montenegro for a Serbia health project April 17, 2003 [Internet]. Washington: The World Bank Group; 2003. http://documents.worldbank.org/curated/en/285761468777609155/pdf/256561YF1Serbia0Health0Project.pdf (accessed March 2, 2016).Google Scholar
6 National Assembly of the Republic of Serbia. Health Insurance Law. [Internet]. Serbia: “Official Gazette of the RS, No.10, 2016”; 2016 [cited 2016 Apr 2]. http://www.rfzo.rs/download/zakoni/Zakon_o_zdrav_osiguranju01042016.pdf (accessed April 2, 2016).Google Scholar
7 National Assembly of the Republic of Serbia. Law on contributions for Mandatory Social Insurance [Internet]. Serbia: “Official Gazette of the RS, No. 5, 2016”; 2016. http://www.paragraf.rs/propisi/zakon_o_doprinosima_za_obavezno_socijalno_osiguranje.html (accessed November 30, 2016).Google Scholar
8 Chamber of Commerce and Industry of Serbia [Internet]. Pharmaceutical and Medical Industry; c2016. http://www.pks.rs/PrivredaSrbije.aspx?id=1804&p=2& (accessed December 8, 2016).Google Scholar
9 National Health Insurance Fund. Health Care Plan by the compulsory health insurance in the Republic of Serbia in 2013 [Internet]. Serbia: National Health Insurance Fund; 2013. http://www.rfzo.rs/download/plan%20zz/planZZ-2013.pdf (accessed April 2, 2016).Google Scholar
10 National Assembly of the Republic of Serbia. Health Care Law [Internet]. Serbia: “Official Gazette of the RS, No. 106, 2015”; 2015. http://www.zdravlje.gov.rs/downloads/2016/Januar/Januar2016ZakonOZZ.pdf (accessed April 2, 2016).Google Scholar
11 Boričić, K, Vasić, M, Grozdanov, J, et al. Results of the National Health Survey of Serbia, 2013 [Internet]. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”; c2014. http://www.batut.org.rs/download/publikacije/2013SerbiaHealthSurvey.pdf (accessed April 2, 2016).Google Scholar
12 The World Bank. International bank for reconstruction and development: project appraisal document on a proposed loan in the amount of EUR 29.1 million (US$40 million equivalent) to the Republic of Serbia for a second Serbia health project (P129539) [Internet]. Washington: The World Bank Group; c2014. http://documents.worldbank.org/curated/en/969641468102535325/pdf/819240PAD0P129010Box382122B00OUO090.pdf (accessed March 2, 2016).Google Scholar
13 National Assembly of the Republic of Serbia. Law on Medicines and Medical Devices. [Internet]. Serbia: “Official Gazette of the RS, No.30, 2010 and 107, 2012”; 2012. http://www.rfzo.rs/download/zakoni/zakon_lekovi22112012.pdf (accessed April 2, 2016).Google Scholar
14 Government of Republic of Serbia. The Decision of the highest prices of drugs for use in human medicine, whose regime issuing prescription [Internet]. Serbia: “Official Gazette” No. 86/15, 90/15, 12/16, 33/16, 48/16, 63/16 and 95/16); 2016. http://www.rfzo.rs/download/odluke/Odluka_lekovi-27052016.pdf (accessed December 25, 2016).Google Scholar
15 National Health Insurance Fund. Rulebook on the conditions, criteria, the way and procedure for placing the drug on the list of drugs, amending the list of drugs, or for removing the drug from the Drug List [Internet]. Serbia: “Official Gazette of the RS”, No. 41/14, 125/14 and 48/15); 2015. http://www.rfzo.rs/download/pravilnici/lekovi/Pravilnik_uslovi_ListaLekova-10062015.pdf (accessed April 2, 2016).Google Scholar
16 National Health Insurance Fund. Rulebook on the Drug List prescribed and issued at the expense of mandatory health insurance [Internet]. Serbia: “Official Gazette of the RS”, No. 65/15, 71/15, 104/15, 24/16, 57/16, 61/16, 78/16, 89/16 and 101/16); 2016. http://www.rfzo.rs/download/pravilnici/lekovi/Pravilnik_o_listi_lekova.pdf (accessed December 21, 2016).Google Scholar
17 National Health Insurance Fund. Rulebook on the Drug List prescribed and issued at the expense of mandatory health insurance. List A [Internet]. Serbia: “Official Gazette of the RS”, No. 65/15, 71/15, 104/15, 24/16, 57/16, 61/16, 78/16, 89/16 and 101/16); 2016. http://www.rfzo.rs/download/pravilnici/lekovi/A%20lista%20-%20primenjuje%20se%20od%2001.01.2017.%20god.pdf (accessed December 21, 2016).Google Scholar
18 National Health Insurance Fund. Rulebook on the Drug List prescribed and issued at the expense of mandatory health insurance. List A1 [Internet]. Serbia: “Official Gazette of the RS”, No. 65/15, 71/15, 104/15, 24/16, 57/16, 61/16, 78/16, 89/16 and 101/16); 2016. http://www.rfzo.rs/download/pravilnici/lekovi/A1%20lista%20-%20primenjuje%20se%20od%2001.01.2017.pdf (accessed December 21, 2016).Google Scholar
19 Davis, S. Assessing technologies that are not cost-effective at a zero price, 2014 [Internet]. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; c2014. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0088909/pdf/PubMedHealth_PMH0088909.pdf (accessed April 2, 2016).Google Scholar
20 National Health Insurance Fund. Rulebook on the Drug List prescribed and issued at the expense of mandatory health insurance. List C [Internet]. Serbia: “Official Gazette of the RS”, No. 65/15, 71/15, 104/15, 24/16, 57/16, 61/16, 78/16, 89/16 and 101/16); 2016. http://www.rfzo.rs/download/pravilnici/lekovi/C%20lista-primenjuje%20se%20od%2017.12.2016.%20god.pdf (accessed December 21, 2016).Google Scholar
21 Council of the European Union. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ 11 February1989, L40/8, 8–11. https://publications.europa.eu/en/publication-detail/-/publication/daf5b7f2-c848-4b7f-a77b-f9ab8e340155/language-en (accessed April 2, 2016).Google Scholar